POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride (KCl) dissociation yields potassium ions that maintain intracellular fluid volume, transmembrane electrochemical gradients, and action potentials in excitable tissues. It repletes potassium deficits and prevents hypokalemia. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid osmolality and volume.
| Metabolism | Potassium is not metabolized; it is primarily excreted renally. Sodium and chloride are also not metabolized; they are excreted mainly by the kidneys. |
| Excretion | Renal: >90% as potassium ion; negligible biliary/fecal excretion under normal conditions. |
| Half-life | Not applicable as a drug; potassium homeostasis is tightly regulated. Serum potassium has a distribution half-life of ~1-1.5 h, with renal elimination half-life depending on glomerular filtration and tubular secretion, typically 6-8 h in normal renal function. |
| Protein binding | Negligible; potassium is freely ionized and not significantly protein-bound. |
| Volume of Distribution | Approximately 0.5 L/kg (total body water); primarily extracellular, with intracellular distribution regulated by Na+/K+ ATPase. |
| Bioavailability | IV: 100%. Not administered orally in this formulation. |
| Onset of Action | IV infusion: Immediate (within minutes) as potassium is directly administered into the bloodstream. |
| Duration of Action | Duration depends on infusion rate and renal function; a single dose effect lasts until potassium is redistributed and excreted. Continuous infusion maintains steady state. |
Intravenous infusion. Adult dose: 10-20 mEq/hour of potassium chloride, typically administered in a concentration of 0.22% (which is 2 mEq/100 mL) in 0.9% sodium chloride. Rate should not exceed 10 mEq/hour for non-emergency situations; maximum daily dose is 200 mEq.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 25-50% and monitor potassium levels closely. GFR <30 mL/min: avoid use or use with extreme caution, reduce dose by at least 50% and frequent monitoring. |
| Liver impairment | No specific dose adjustment required for hepatic impairment. However, monitor serum potassium levels regularly. In severe hepatic impairment (Child-Pugh class C), consider potential reduced drug clearance and monitor electrolytes more frequently. |
| Pediatric use | Weight-based intravenous infusion: 0.5-1 mEq/kg/dose, maximum single dose 2 mEq/kg, to be infused at a rate not exceeding 0.5 mEq/kg/hour. Dilute to a maximum concentration of 0.22% (2 mEq/100 mL) in 0.9% sodium chloride. |
| Geriatric use | Elderly patients may have reduced renal function; start at lower end of dosing range (e.g., 5-10 mEq/hour) and titrate based on serum potassium levels. Monitor renal function and electrolyte levels frequently. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium and sodium are normal constituents of breast milk. M/P ratio not applicable. Compatible with breastfeeding at recommended doses. |
| Teratogenic Risk | Potassium chloride and sodium chloride are physiological ions and not teratogenic. No fetal risk at therapeutic doses. Trimester-specific risks: None. |
■ FDA Black Box Warning
Concentrated potassium chloride injection (not applicable to this dilute solution) has a black box warning for fatal cardiac arrhythmias if given undiluted. For 0.22% KCl in 0.9% NaCl, no specific black box warning exists; however, the risk of hyperkalemia necessitates careful monitoring.
| Common Effects | fluid replacement |
| Serious Effects |
Hyperkalemia, severe renal impairment (oliguria, anuria), untreated Addison's disease, acute dehydration, heat cramps, concurrent use of potassium-sparing diuretics (absolute). Relative: metabolic acidosis, cardiac conditions sensitive to potassium levels.
| Precautions | Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia. Monitor serum potassium, sodium, and chloride levels, and ECG. Avoid rapid infusion. Risk of hyperkalemia may be increased with potassium-sparing diuretics, ACE inhibitors, or ARBs. Do not use in patients with oliguria, anuria, or untreated Addison's disease. |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes, renal function, and fluid status. Assess for signs of hyperkalemia (ECG changes) and hypernatremia. Fetal monitoring not routinely required. |
| Fertility Effects | No known effects on fertility. |